Replies to post #121574 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I was wondering the same thing. As TOB has pointed out, Nasdaq rules are not set in stone. One can only hope that the current SP isn't a problem.

Looks like CTIX has applied for the Pediatric Disease Priority Review Voucher for retinoblastoma.

"In August 2015 an application was submitted to the FDA requesting a Rare Disease Designation for Kevetrin for the treatment of pediatric retinoblastoma."

I know of at least one situation in the past where a stock uplisted to NASDAQ while being below $2, the explanation was that qualification occurred during a period when the pps was above $2. This might just be wishful thinking, but if audited financials is what NASDAQ has been waiting for, might the pps timeframe of question fall within the same audited financial timeframe? CTIX was well above $2 for months leading up to fiscal year end - could we uplist next week???